About Biosyntech
Biosyntech is a company based in Laval (Canada) founded in 1994 was acquired by Piramal Group in June 2010. Biosyntech has raised $1.4 million across 1 funding round from investors including Piramal Group, ProQuest Investments and Highland Capital Partners. Biosyntech operates in a competitive market with competitors including Augmenix, AmacaThera, QBiotics, MediWound and Ilya Pharma, among others.
- Headquarter Laval, Canada
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.4 M (USD)
in 1 rounds
-
Latest Funding Round
$1.4 M (USD), Series A
Jun 01, 2009
-
Investors
Piramal Group
& 4 more
-
Employee Count
Not available
-
Acquired by
Piramal Group
(Jun 22, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Biosyntech
Biosyntech has successfully raised a total of $1.4M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.4 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biosyntech
Biosyntech has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Piramal Group, ProQuest Investments and Highland Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital investment and entrepreneur support services.
|
Locked | Locked | Locked | |
|
VC firm focusing on life science sector
|
Locked | Locked | Locked |
Investor details for Biosyntech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosyntech
Investment portfolio details for Biosyntech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biosyntech
Detailed financials for Biosyntech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biosyntech Comparisons
Peer comparison for Biosyntech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biosyntech
Biosyntech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Augmenix, AmacaThera, QBiotics, MediWound and Ilya Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Hydrogel spacers are provided for prostate cancer radiation therapy.
|
|
| Locked | Locked | Locked |
Injectable hydrogel platform developed for therapeutic medical applications.
|
|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Enzymatic therapies for tissue repair and regeneration are developed.
|
|
| Locked | Locked | Locked |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| Locked | Locked | Locked |
Macrophage cell therapies are developed for inflammatory and liver diseases.
|
Detailed competitors of Biosyntech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biosyntech
Complete news archive for Biosyntech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosyntech
Biosyntech was founded in 1994 and raised its 1st funding round 15 years after it was founded.
Biosyntech is headquartered in Laval, Canada. It is registered at Laval, Quebec, Canada.
Biosyntech is a funded company, having raised a total of $1.4M across 1 funding round to date.
BioSyntech was founded in 1994 in Laval, Canada, as a biotechnology firm. Chitosan-based hydrogels, known as BST-Gel, were developed for cartilage repair and therapeutic agent delivery. These thermogels, liquid at low temperatures and solid at body temperature, were designed for injection or application to sites like damaged cartilage, bone, and chronic wounds. Bankruptcy was filed in May 2010, followed by acquisition by Piramal Healthcare in June 2010.
Biosyntech's top competitors include Ilya Pharma, AmacaThera and Augmenix.
Biosyntech has 5 investors. Key investors include Piramal Group, ProQuest Investments, Highland Capital Partners, Fonds de solidarite FTQ, and Pappas Capital.